The microtubule cytoskeleton participates in control of beta2 integrin avidity.
Leukocyte avidity is regulated by cytoskeletal constraints, which keep beta(2) integrins in an inactive mode. Releasing these constraints results in increased lateral mobility and clustering of integrins, effectively activating adhesion. At least part of the constraint on beta(2) integrins is due to actin; whether other cytoskeletal components are involved has not previously been investigated. Microtubules are a candidate for control of integrin rearrangement, because they modulate focal adhesions, which are sites of interaction between integrins and the cytoskeleton. Here we report that both depolymerization of microtubules by colchicine or nocodazole and stabilization of microtubules by taxol increased the lateral mobility of beta(2) integrins, activating adhesion. Increased integrin mobility was accompanied by an increase in tyrosine phosphorylation of paxillin, a biochemical event associated with activation of beta(2) integrins. Further, C3 exoenzyme, an inhibitor of Rho, blocked induction of integrin mobility by nocodazole, but not by taxol, suggesting that there are multiple microtubule-dependent pathways to integrin rearrangement, only some of which require Rho activity. Taken together, our data suggest that a dynamic microtubule system is required to regulate integrin-cytoskeleton interactions. Furthermore, these data demonstrate that microtubules participate in control of integrin rearrangement, one of the earliest steps in activation of integrin-mediated adhesion.
Zhou
X
X
Department of Oral Biology, College of Dentistry, University of Illinois at Chicago, 60612, USA.
Li
J
J
Kucik
D F
DF
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D018821:CD18 Antigens / Q000378:metabolism*; D002448:Cell Adhesion; D002449:Cell Aggregation; D002460:Cell Line; D002461:Cell Line, Transformed; D003078:Colchicine / Q000494:pharmacology; D003598:Cytoskeletal Proteins / Q000378:metabolism; D003599:Cytoskeleton / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000378:metabolism; D006074:Gout Suppressants / Q000494:pharmacology; D006801:Humans; D016023:Integrins / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D018715:Microscopy, Video; D008870:Microtubules / Q000378:metabolism*; D015233:Models, Statistical; D015739:Nocodazole / Q000494:pharmacology; D017239:Paclitaxel / Q000494:pharmacology; D051419:Paxillin; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation; D011485:Protein Binding; D011493:Protein Kinase C / Q000378:metabolism; D015398:Signal Transduction; D013755:Tetradecanoylphorbol Acetate / Q000378:metabolism; D013997:Time Factors; D014443:Tyrosine / Q000378:metabolism
D000970:Antineoplastic Agents; D018821:CD18 Antigens; D003598:Cytoskeletal Proteins; D004791:Enzyme Inhibitors; D006074:Gout Suppressants; D016023:Integrins; C496061:PXN protein, human; D051419:Paxillin; D010750:Phosphoproteins; C496062:Pxn protein, mouse; D014443:Tyrosine; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate; D017239:Paclitaxel; D015739:Nocodazole; D003078:Colchicine